Mitigation may be better than quarantine against Covid-19, says GlobaData

Mitigation might be a better strategy than quarantine to combat the spread of Covid-19, says data and analytics company, GlobalData.

As the coronavirus continues to spread beyond China, GlobalData says that governments should start to consider focussing on mitigation and bolstering the health system for early detection and care of patients.

The main strategy to battle the spread of Covid-19 has been one of containment and quarantine of outbreak areas, with the most severe travel restrictions taking place within China. However, as the virus is trending toward pandemic status with multiple clusters outside of China, quarantine may no longer be the right approach to limit further outbreaks.

“Travel restriction from outbreak countries might not be an effective strategy as it was when the infection was still localized. Tracking who had travelled where from multiple international locations will be extremely difficult,” said Bishal Bhandari, Senior Epidemiologist at GlobalData.

“Travel out of Italy, Korea and Iran had not been restricted in the days before the concerning reports of new infections, and it is likely that people have carried the virus out of those areas already. Indeed, more than 14 countries have already reported cases exported from Italy.

“Governments should consider focusing on mitigation measures to help slow the spread of infections and reduce the severity of the outbreak.

“The strategy of mitigation or slowing the spread by closing schools or mass gatherings could be more effective in countries where cities and towns cannot be locked down and complete ban on movement of people is not possible.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...